STERIS Announces Financial Results for Fiscal 2027 Second Quarter

STERIS delivered strong Q2 growth and raised full-year earnings guidance on solid segment performance.

What the company is saying

STERIS plc reports a 9% year-over-year revenue increase to $1.6 billion for Q2 fiscal 2027, with constant currency organic growth at 8%. The company highlights robust Life Sciences performance, which led to an upward revision of full-year segment expectations. Management, led by President and CEO Dan Carestio, frames the quarter as evidence of stable underlying demand and effective commercial execution. The narrative emphasizes the benefit of $20 million in tariff refunds and notes that gross tariff costs remained flat at $15 million. STERIS details a new restructuring plan, primarily in Healthcare, projecting $45 million in total charges and $9 million in annualized savings. The company raises its adjusted EPS outlook for fiscal 2027 to $11.35–$11.55, up from $11.10–$11.30, explicitly attributing $0.18 per share of this increase to tariff refunds. The tone is confident, with forward-looking statements presented as extensions of current momentum rather than speculative leaps.

What the data suggests

The financials show broad-based improvement: total revenue rose 9% to $1.6 billion, and net income increased to $213.7 million ($2.19 per diluted share) from $191.9 million ($1.94) a year ago. Adjusted net income climbed to $286.8 million ($2.94 per share) from $244.5 million ($2.47). Healthcare revenue reached $1.1 billion, up 9%, with 10% growth in both service and consumables and a 4% rise in capital equipment. Healthcare operating income improved to $269.2 million. Applied Sterilization Technologies revenue grew 5% to $295.6 million, though capital equipment sales fell 21%; segment operating income rose to $132.1 million. Life Sciences posted the strongest gains, with revenue up 18% to $170.6 million and operating income up to $75.8 million, driven by a 53% surge in capital equipment revenue. Cash flow from operations declined to $656.1 million from $707.8 million, and free cash flow fell to $492.5 million from $527.7 million, mainly due to lower working capital contribution despite higher net income. The restructuring plan introduces $45 million in charges ($10 million cash, $35 million non-cash), with $25 million realized in Q2, and targets $9 million in annual savings. The updated fiscal 2027 outlook maintains 7–8% reported revenue growth and 6–7% constant currency organic growth, while raising adjusted EPS guidance to $11.35–$11.55. The data supports management’s confidence, though the cash flow dip and restructuring costs are notable.

Analysis

The announcement's tone is positive but proportionate to the strong, realised financial results disclosed for the quarter. The company provides detailed, audited figures for revenue, net income, adjusted net income, operating income by segment, and cash flow, all showing year-over-year improvement. Forward-looking statements (such as restructuring savings and updated outlooks) are clearly separated from realised results and do not dominate the narrative. The restructuring plan involves a moderate capital outlay ($10 million cash, $35 million non-cash), but this is not material relative to the company's cash flow and is paired with a credible, quantified savings target. The majority of key claims are realised and supported by hard data, with only a minority of forward-looking projections. There is no evidence of narrative inflation or overstatement; language is factual and supported by the disclosed numbers.

Risk flags

• ●Cash flow from operations and free cash flow both declined year-over-year, falling to $656.1 million and $492.5 million respectively, mainly due to a lower contribution from working capital. This could constrain flexibility if the trend persists, even as net income rises.
• ●The restructuring plan involves $45 million in charges, with $25 million already recognized in Q2. While annualized savings of $9 million are projected, these will only partially materialize in fiscal 2028 and fully in subsequent years, introducing execution risk around cost reduction.
• ●Applied Sterilization Technologies saw a 21% drop in capital equipment revenue despite overall segment growth, indicating potential volatility or weakness in that product line that could affect future segment performance.
• ●The raised earnings guidance includes a $0.18 per share benefit from tariff refunds, a non-recurring item. Future results may not benefit from similar one-time gains, so underlying growth must compensate for this temporary boost.
• ●The pending Xodus Medical acquisition is not yet reflected in the outlook, so integration and performance risks remain unquantified until the deal closes and new guidance is issued.

Bottom line

STERIS delivered strong Q2 results, with revenue, net income, and adjusted EPS all rising solidly year-over-year. Segment performance was robust, especially in Life Sciences, and the company raised its full-year adjusted EPS outlook to $11.35–$11.55, partly due to a $0.18 per share benefit from tariff refunds. Cash flow declined due to working capital swings, and a new restructuring plan will incur $45 million in charges for $9 million in annualized savings, with most benefits realized after fiscal 2027. While the outlook is credible and supported by realised numbers, investors should watch for continued cash flow pressure, the impact of restructuring execution, and the integration of the pending Xodus Medical acquisition. The most important takeaway is that STERIS is executing well operationally, but future growth will need to come from core demand and efficiency as one-time tariff benefits fade.

Announcement summary

(NYSE:STE) STERIS plc announced financial results for its fiscal 2027 second quarter ended September 30, 2026. Total revenue for the second quarter increased 9% to $1.6 billion compared with $1.5 billion in the second quarter of fiscal 2026. Constant currency organic revenue growth was 8% in the second quarter. Net income for the second quarter was $213.7 million, or $2.19 per diluted share, compared with $191.9 million, or $1.94 per diluted share, in the second quarter of fiscal 2026. Adjusted net income for the second quarter of fiscal 2027 was $286.8 million, or $2.94 per diluted share, compared with $244.5 million or $2.47 per diluted share in the previous year’s second quarter. The pre-tax impact of tariff refunds on as reported results was a benefit of approximately $20 million for the quarter. Gross tariff costs were flat with the prior year at $15 million for the quarter. Healthcare revenue as reported grew 9% in the second quarter to $1.1 billion compared with $1.0 billion in the second quarter of fiscal 2026. Healthcare segment performance reflected 10% improvement in service revenue, 10% growth in consumables revenue, and a 4% increase in capital equipment revenue. Constant currency organic revenue growth for Healthcare was 7%. Healthcare operating income was $269.2 million compared with $259.5 million in last year’s second quarter. Applied Sterilization Technologies (AST) revenue increased 5% as reported to $295.6 million compared with $281.5 million in the same period last year, with 5% growth in service revenue and a 21% decline in capital equipment revenue. Constant currency organic revenue growth for AST was 5%. AST segment operating income was $132.1 million in the second quarter of fiscal 2027, compared with $127.6 million in the same period last year. Life Sciences second quarter revenue as reported increased 18% to $170.6 million compared with $145.0 million in the second quarter of fiscal 2026, reflecting 53% growth in capital equipment revenue, 9% improvement in consumables revenue, and 5% growth in service revenue. Constant currency organic revenue for Life Sciences increased 18%. Life Sciences operating income increased to $75.8 million in the second quarter of fiscal 2027 compared with $59.9 million in the prior year’s second quarter. Net cash provided by operations for the first six months of fiscal 2027 was $656.1 million, compared with $707.8 million in the first six months of fiscal 2026. Free cash flow for the first six months of fiscal 2027 was $492.5 million compared with $527.7 million in the prior year period. During the quarter, the Company approved a separate targeted restructuring plan, in addition to the plan announced on August 5, 2026, including targeted facility realignment, product rationalization and select organizational realignment, primarily in the Healthcare segment. The Company anticipates total charges of approximately $45 million associated with the plan, including approximately $10 million in cash expenditures and $35 million in non-cash charges. Charges associated with the second quarter of fiscal 2027 are approximately $25 million. The plan is expected to generate annualized savings of approximately $9 million, with a portion realized in fiscal 2028 and the full benefit realized in subsequent fiscal years. The Company is updating its prior outlook for revenue and earnings for fiscal 2027. Expectations for consolidated revenue growth are unchanged and include as reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%. Adjusted earnings per diluted share are now anticipated to be in the range of $11.35 to $11.55, an increase from prior expectations of $11.10 to $11.30. The revised outlook includes the benefit of approximately $0.18 from tariff refunds received year-to-date. Segment constant currency organic revenue growth outlooks are: Healthcare 6-7% (unchanged), Applied Sterilization Technologies 6-7% (prior 7-8%), and Life Sciences 9-10% (prior 6-7%). STERIS will provide a revised fiscal 2027 outlook inclusive of the proposed Xodus Medical acquisition after closing. Dan Carestio, President and CEO of STERIS, stated that Life Sciences delivered particularly strong performance in the quarter, giving confidence to raise expectations for the segment for the full year.

Disagree with this article?